Patents by Inventor Sheue-Fang Shih

Sheue-Fang Shih has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10322086
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 18, 2019
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Patent number: 10286076
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: May 14, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10058616
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 28, 2018
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Publication number: 20180193461
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Application
    Filed: March 6, 2018
    Publication date: July 12, 2018
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Publication number: 20180169248
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: February 5, 2018
    Publication date: June 21, 2018
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Patent number: 9987360
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: June 5, 2018
    Assignees: TAIWAN LIPOSOME CO. LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20170367979
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 28, 2017
    Inventors: KEELUNG HONG, LUKE S. S. GUO, YUN-LONG TSENG, SHEUE-FANG SHIH, PO-CHUN CHANG, CHIH-CHIANG TSAI, HONG-HUI LIN
  • Patent number: 9789062
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: October 17, 2017
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Publication number: 20150174069
    Abstract: Disclosed herein are methods of treating arthritis, comprising administering a sustained release composition comprising liposomes comprising one or more phospholipids, cholesterol, and a therapeutic agent. The sustained release composition can be administered intraarticularly.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 25, 2015
    Inventors: Keelung Hong, Luke S.S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Publication number: 20150147320
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: December 16, 2014
    Publication date: May 28, 2015
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Patent number: 8956600
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 17, 2015
    Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20150011520
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 8, 2015
    Inventors: Keelung Hong, Luke S.S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Publication number: 20140287025
    Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.
    Type: Application
    Filed: April 9, 2014
    Publication date: September 25, 2014
    Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.
    Inventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
  • Publication number: 20140193486
    Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 10, 2014
    Applicants: TLC Biopharmaceuticals, Inc., Taiwan Liposome Company
    Inventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
  • Publication number: 20110033468
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: August 10, 2009
    Publication date: February 10, 2011
    Applicant: Taiwan Liposome Co., Ltd
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S.S. Guo, Keelung Hong
  • Patent number: 7740844
    Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: June 22, 2010
    Assignees: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih
  • Publication number: 20090269336
    Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.
    Type: Application
    Filed: April 29, 2008
    Publication date: October 29, 2009
    Applicants: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.
    Inventors: Keelung Hong, Luke S.S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih
  • Publication number: 20080118500
    Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.
    Type: Application
    Filed: November 16, 2007
    Publication date: May 22, 2008
    Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.
    Inventors: Jun-Jen Liu, Yun-Long Tseng, Sheue-Fang Shih, Luke S.S. Guo, Keelung Hong